Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49.

Article  PubMed  Google Scholar 

Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48.

Article  PubMed  Google Scholar 

Garassino MC, Gadgeel S, Speranza G, Felip E, Esteban E, Dómine M, et al. Pembrolizumab plus pemetrexed and platinum in nonsquamous non-small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study. J Clin Oncol. 2023;41(11):1992–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Novello S, Kowalski DM, Luft A, Gümüş M, Vicente D, Mazières J, et al. Pembrolizumab plus chemotherapy in squamous non-small-cell lung cancer: 5-year update of the phase III KEYNOTE-407 study. J Clin Oncol. 2023;41(11):1999–2006.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score ≥ 50. J Clin Oncol. 2021;39(21):2339–49.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Paz-Ares LG, Ciuleanu TE, Cobo M, Bennouna J, Schenker M, Cheng Y, et al. First-line nivolumab plus ipilimumab with chemotherapy versus chemotherapy alone for metastatic NSCLC in CheckMate 9LA: 3-year clinical update and outcomes in patients with brain metastases or select somatic mutations. J Thorac Oncol. 2023;18(2):204–22.

Article  CAS  Google Scholar 

Boyero L, Sánchez-Gastaldo A, Alonso M, Noguera-Uclés JF, Molina-Pinelo S, Bernabé-Caro R. Primary and acquired resistance to immunotherapy in lung cancer: unveiling the mechanisms underlying of immune checkpoint blockade therapy. Cancers (Basel). 2020;12(12):3729.

Article  CAS  PubMed  Google Scholar 

Schoenfeld AJ, Hellmann MD. Acquired resistance to immune checkpoint inhibitors. Cancer Cell. 2020;37(4):443–55. Overview of mechanisms of acquired resistance to ICIs in solid tumors, analysis of the barriers to progress and emerging clinical reports.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Xia Y, Tian X, Wang J, Qiao D, Liu X, Xiao L, et al. Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: a case report. Oncol Lett. 2018;16(6):6998–7007.

CAS  PubMed  PubMed Central  Google Scholar 

Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462.

Article  PubMed  PubMed Central  Google Scholar 

Schmitt TM, Ragnarsson GB, Greenberg PD. T cell receptor gene therapy for cancer. Hum Gene Ther. 2009;20(11):1240–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scholten KBJ, Kramer D, Kueter EWM, Graf M, Schoedl T, Meijer CJLM, et al. Codon modification of T cell receptors allows enhanced functional expression in transgenic human T cells. Clin Immunol. 2006;119(2):135–45.

Article  CAS  PubMed  Google Scholar 

Fukuyama T, Hanagiri T, Takenoyama M, Ichiki Y, Mizukami M, So T, et al. Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res. 2006;66(9):4922–8.

Article  CAS  PubMed  Google Scholar 

Hsu R, Baca Y, Xiu J, Wang R, Bodor JN, Kim C, et al. Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas. Oncotarget. 2021;12(25):2449–58.

Article  PubMed  PubMed Central  Google Scholar 

Tajima K, Obata Y, Tamaki H, Yoshida M, Chen YT, Scanlan MJ, et al. Expression of cancer/testis (CT) antigens in lung cancer. Lung Cancer. 2003;42(1):23–33.

Article  PubMed  Google Scholar 

Schultz-Thater E, Piscuoglio S, Iezzi G, Le Magnen C, Zajac P, Carafa V, et al. MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies. Int J Cancer. 2011;129(5):1137–48.

Article  CAS  PubMed  Google Scholar 

Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res. 2005;11(22):8055–62.

Article  CAS  PubMed  Google Scholar 

Judd J, Abdel Karim N, Khan H, Naqash AR, Baca Y, Xiu J, et al. Characterization of KRAS mutation subtypes in non-small cell lung cancer. Mol Cancer Ther. 2021;20(12):2577–84.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Mitsudomi T, Yatabe Y. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer. Cancer Sci. 2007;98(12):1817–24.

Article  CAS  PubMed  Google Scholar 

Miller CW, Simon K, Aslo A, Kok K, Yokota J, Buys CH, et al. p53 mutations in human lung tumors. Cancer Res. 1992;52(7):1695–8.

CAS  PubMed  Google Scholar 

Yoshida N, Abe H, Ohkuri T, Wakita D, Sato M, Noguchi D, et al. Expression of the MAGE-A4 and NY-ESO-1 cancer-testis antigens and T cell infiltration in non-small cell lung carcinoma and their prognostic significance. Int J Oncol. 2006;28(5):1089–98.

CAS  PubMed  Google Scholar 

Thomas R, Al-Khadairi G, Roelands J, Hendrickx W, Dermime S, Bedognetti D, et al. NY-ESO-1 based immunotherapy of cancer: current perspectives. Front Immunol. 2018;9(947) Available from: https://pubmed.ncbi.nlm.nih.gov/29770138/

Blumenschein GR, Devarakonda S, Johnson M, Moreno V, Gainor J, Edelman MJ, et al. Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10+ advanced non-small cell lung cancer. J Immunother Cancer. 2022;10(1):e003581. Trial reporting feasibility of MAGE-A10 TCR T cells ACT in NSCLC.

Article  PubMed  PubMed Central  Google Scholar 

Ellis JM, Henson V, Slack R, Ng J, Hartzman RJ, Katovich HC. Frequencies of HLA-A2 alleles in five U.S. population groups. Predominance Of A*02011 and identification of HLA-A*0231. Hum Immunol. 2000;61(3):334–40.

Article  CAS  PubMed  Google Scholar 

Janelle V, Delisle JS. T-cell dysfunction as a limitation of adoptive immunotherapy: current concepts and mitigation strategies. Cancers (Basel). 2021;13(4):598.

Article  CAS  PubMed  Google Scholar 

Chmielewski M, Abken H. TRUCKs: the fourth generation of CARs. Expert Opin Biol Ther. 2015;15(8):1145–54.

Article  CAS  PubMed  Google Scholar 

Soini Y, Pirinen R, Takasawa K, Osanai M, Takasawa A. Claudin 6 is associated with a short survival and a short recurrent free interval in non-small cell lung carcinoma. Pol J Pathol. 2022;73(1):1–5.

Article  PubMed  Google Scholar 

Blanco R, Rengifo CE, Cedeño M, Frómeta M, Rengifo E, Ramos-Suzarte M. Tumor expression of the carcinoembryonic antigen correlates with high mitotic activity and cell pleomorphism index in lung carcinoma. Journal Hist. 2013;2013:e827089.

Google Scholar 

Sridhar SS, Seymour L, Shepherd FA. Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol. 2003;4(7):397–406.

Article  CAS  PubMed  Google Scholar 

Aviel-Ronen S, Lau SK, Pintilie M, Lau D, Liu N, Tsao MS, et al. Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma. Mod Pathol. 2008;21(7):817–25.

Article  CAS  PubMed  Google Scholar 

Zhang S, Chen L, Wang-Rodriguez J, Zhang L, Cui B, Frankel W, et al. The onco-embryonic antigen ROR1 is expressed by a variety of human cancers. Am J Pathol. 2012;181(6):1903–10.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Frierson HF, Moskaluk CA, Powell SM, Zhang H, Cerilli LA, Stoler MH, et al. Large-scale molecular and tissue microarray analysis of mesothelin expression in common human carcinomas. Hum Pathol. 2003;34(6):605–9.

Article  CAS  PubMed  Google Scholar 

Sun Y, Wang Y, Zhao J, Gu M, Giscombe R, Lefvert AK, et al. B7-H3 and B7-H4 expression in non-small-cell lung cancer. Lung Cancer. 2006;53(2):143–51.

Article  PubMed  Google Scholar 

Hirsch FR, Varella-Garcia M, Franklin WA, Veve R, Chen L, Helfrich B, et al. Evaluation of HER-2/neu gene amplification and protein expression in non-small cell lung carcinomas. Br J Cancer. 2002;86(9):1449–56.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Feng K, Guo Y, Dai H, Wang Y, Li X, Jia H, et al. Chimeric antigen receptor-modified T cells for the immunotherapy of patients with EGFR-expressing advanced relapsed/refractory non-small cell lung cancer. Sci China. Life Sci. 2016;59(5):468–79. Trial reporting feasibility and safety of EGFR CAR-T in NSCLC.

Article  CAS  Google Scholar 

Zhang Y, Zhang Z, Ding Y, Fang Y, Wang P, Chu W, et al. Phase I clinical trial of EGFR-specific CAR-T cells generated by the piggyBac transposon system in advanced relapsed/refractory non-small cell lung cancer patients. J Cancer Res Clin Oncol. 2021;147(12):3725–34. Trial reporting feasibility and safety of EGFR CAR-T in NSCLC.

Article  CAS  PubMed